BioCryst Pharmaceuticals (NASDAQ:BCRX) Announces Quarterly Earnings Results

BioCryst Pharmaceuticals (NASDAQ:BCRX) released its quarterly earnings data on Thursday. The biotechnology company reported $1.12 earnings per share for the quarter, beating analysts’ consensus estimates of $0.07 by $1.05, Briefing.com reports. BioCryst Pharmaceuticals had a negative return on equity of 4.24% and a negative net margin of 1.46%.The firm had revenue of $163.28 million during the quarter, compared to analyst estimates of $151.32 million. During the same quarter in the prior year, the firm posted ($0.13) earnings per share. The business’s quarterly revenue was up 209.1% compared to the same quarter last year.

Here are the key takeaways from BioCryst Pharmaceuticals’ conference call:

• BioCryst closed 2025 with strong ORLADEYO sales of $601.8M (up 38% YoY; 43% ex‑Europe) and launched ORLADEYO Pellets for ages 2–<12, which management expects to increase pediatric diagnosis and long‑term patient growth.
• Navenibart Phase 3 (Alpha Orbit) is recruiting well with ~145 patients expected by mid‑2026; Phase 2 showed ~90–92% mean attack reductions and a mean attack rate of 0.16/month, and the company is targeting a BLA submission by end‑2027 and approval in late‑2028.
• The company reported record non‑GAAP operating profit of $214M, ended 2025 with $337.5M in cash/investments and secured a $400M financing facility with Blackstone, highlighting strong liquidity and capital optionality.
• Early‑stage KLK5 inhibitor BCX‑17725 completed healthy‑volunteer dosing with favorable safety and epidermal distribution and is moving into patient cohorts (up to 12 in Part 4) with data expected by year‑end 2026, offering pipeline optionality but still early evidence.
• Management warns of a likely Q1 revenue dip due to reauthorization season and expects higher non‑GAAP R&D spend in 2026 (guidance OpEx $450–$470M) to complete navenibart Phase 3 and CMC work, which will raise near‑term operating expenses despite a goal to remain profitable.

BioCryst Pharmaceuticals Trading Up 4.6%

Shares of BCRX opened at $7.90 on Friday. The firm’s 50-day moving average price is $7.11 and its 200-day moving average price is $7.40. The firm has a market capitalization of $1.66 billion, a price-to-earnings ratio of -158.00 and a beta of 0.83. BioCryst Pharmaceuticals has a 1-year low of $6.00 and a 1-year high of $11.31.

Analyst Ratings Changes

BCRX has been the subject of several analyst reports. Royal Bank Of Canada dropped their price target on shares of BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating for the company in a research report on Friday, January 30th. HC Wainwright boosted their price objective on shares of BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Citizens Jmp dropped their target price on shares of BioCryst Pharmaceuticals from $27.00 to $25.00 and set a “market outperform” rating for the company in a report on Wednesday, November 5th. Needham & Company LLC cut their target price on BioCryst Pharmaceuticals from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, November 4th. Finally, Evercore began coverage on BioCryst Pharmaceuticals in a report on Wednesday, February 18th. They set an “outperform” rating and a $17.00 price target on the stock. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $19.64.

Insider Transactions at BioCryst Pharmaceuticals

In other BioCryst Pharmaceuticals news, insider Alane P. Barnes sold 91,004 shares of the firm’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $7.10, for a total value of $646,128.40. Following the completion of the sale, the insider directly owned 416,152 shares in the company, valued at $2,954,679.20. This trade represents a 17.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders have sold 183,453 shares of company stock valued at $1,330,965 over the last ninety days. 5.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. CIBC Bancorp USA Inc. purchased a new position in shares of BioCryst Pharmaceuticals during the third quarter valued at approximately $169,000. Banco Bilbao Vizcaya Argentaria S.A. bought a new position in BioCryst Pharmaceuticals during the 4th quarter valued at approximately $148,000. Brooklyn Investment Group purchased a new position in BioCryst Pharmaceuticals during the fourth quarter valued at $144,000. XTX Topco Ltd purchased a new position in BioCryst Pharmaceuticals during the fourth quarter valued at $133,000. Finally, Sherbrooke Park Advisers LLC boosted its holdings in BioCryst Pharmaceuticals by 30.5% in the third quarter. Sherbrooke Park Advisers LLC now owns 16,524 shares of the biotechnology company’s stock worth $125,000 after acquiring an additional 3,866 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals News Roundup

Here are the key news stories impacting BioCryst Pharmaceuticals this week:

• Positive Sentiment: Q4 results materially beat expectations: GAAP EPS $1.12 vs. ~$0.07 consensus and quarterly revenue topped estimates — a clear near‑term catalyst supporting the rally. Zacks: Q4 Earnings & Revenues Surpass Estimates
• Positive Sentiment: Full‑year ORLADEYO net revenue showed strong growth (ORLADEYO net revenue of $601.8M, +38% y/y), reinforcing the company’s commercial momentum. GlobeNewswire: Full‑Year 2025 Results
• Positive Sentiment: BioCryst announced the Astria acquisition and updated guidance, which management says boosts its HAE franchise — a strategic move that should support longer‑term sales and synergies. TipRanks: Astria Acquisition & Guidance
• Positive Sentiment: Analysts are constructive: a consensus “Moderate Buy” rating was reported, reflecting rising sell‑side support after the results and strategic update. AmericanBankingNews: Moderate Buy Consensus
• Neutral Sentiment: Market commentary is assessing whether the recent price rebound leaves BCRX still attractive on valuation — useful context but not an immediate fundamental catalyst. Yahoo Finance: Valuation Analysis
• Neutral Sentiment: The company posted its earnings presentation / call materials for investors to review; these provide detail on drivers and guidance but are informational rather than a new catalyst. Seeking Alpha: Q4 Presentation
• Negative Sentiment: Despite the beats, reported net margin and return on equity remain negative on a GAAP basis, and some sell‑side modeling still reflects a below‑break‑even EPS outlook for the fiscal year — risks for longer‑term valuation. MarketBeat: Q4 Results & Metrics

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.